How Long Do You Stay on 0.25 mg Wegovy?

You stay on 0.25 mg Wegovy for four weeks. That first month is the lowest rung of a five-step dose escalation that gradually brings you up to the full maintenance dose of 2.4 mg per week. The 0.25 mg dose is not meant to produce significant weight loss on its own. Its purpose is to let your body adjust to semaglutide so that side effects, particularly nausea, stay manageable as the dose climbs. Most people spend exactly four weeks at this level before stepping up, though there are situations where a prescriber may extend that window.

Why the Starting Dose Exists

Semaglutide, the active ingredient in Wegovy, mimics a gut hormone called GLP-1 that slows digestion and reduces appetite. The drug has an unusually long half-life of about one week, which is why you inject it only once every seven days.¹ Because the drug clears slowly, each weekly injection adds to whatever is still circulating from the previous one. It takes roughly four to five weeks for blood levels to stabilize at any given dose. Starting at 0.25 mg means the drug builds up gradually, giving your gastrointestinal system time to adapt rather than hitting it with a therapeutically active concentration on day one.

At the 0.25 mg level, most people experience mild or no side effects. Nausea is the most common complaint across the entire escalation, and starting low keeps those early weeks tolerable. Think of it as a ramp. The 0.25 mg phase is not treating your weight yet. It is training your gut to tolerate a medication that, at full strength, will meaningfully change how hungry you feel and how quickly food moves through your digestive tract.

The Full Dose Escalation Schedule

Wegovy’s prescribing schedule moves through five dose levels, each lasting four weeks. The clinical trial protocol followed in large studies lays it out clearly: 0.25 mg per week during weeks one through four, 0.5 mg during weeks five through eight, 1.0 mg during weeks nine through twelve, 1.7 mg during weeks thirteen through sixteen, and then 2.4 mg from week seventeen onward as the maintenance dose.² That means it takes about four months to reach the target dose, with the 0.25 mg phase occupying only the first of those four months.

Each step doubles or nearly doubles the previous dose. Going from 0.25 to 0.5 is a doubling. Going from 0.5 to 1.0 is another doubling. Then 1.0 to 1.7 is a 70% jump, and 1.7 to 2.4 is roughly a 40% increase. The gaps between steps are designed so that side effects at each new dose are annoying but brief, typically fading within a few days to a week as your body catches up.

What Happens If You Skip Steps

The escalation schedule is not a suggestion. Jumping to a higher dose without titrating through the earlier steps can cause serious gastrointestinal problems. A published case report described a 48-year-old woman with type 2 diabetes who resumed semaglutide at 2 mg per week without following the recommended stepwise titration. She developed persistent nausea and vomiting consistent with gastroparesis, a condition where the stomach empties far too slowly.³ That kind of outcome is exactly what the slow ramp is designed to prevent.

This matters for two common scenarios. First, people who stop Wegovy for a while and then restart. If you have been off the medication for more than a few weeks, your body has lost its adaptation, and jumping back to whatever dose you left off at can overwhelm your digestive system. Most prescribers will have you start the escalation over, beginning again at 0.25 mg. Second, people who obtain the medication without a prescription and try to start at a higher dose for faster results. The clinical evidence is clear that this trades modest time savings for a much higher risk of severe nausea, vomiting, and potentially dangerous stomach paralysis.

Can You Stay on 0.25 mg Longer Than Four Weeks?

Yes, and some people do. The four-week window is the standard recommendation, but it is a minimum, not a deadline. If you are still having significant nausea or other GI side effects at the end of your fourth week on 0.25 mg, your prescriber may keep you at that dose for another two to four weeks before stepping up. The logic is straightforward: if your body has not fully adjusted to the current dose, moving to a higher one will only make things worse.

There is no clinical harm in spending extra time at 0.25 mg. The drug is still building in your system, and you are still getting the GI adaptation that will make higher doses more tolerable. What you are not getting is meaningful weight loss. At 0.25 mg, the circulating drug level is well below the therapeutic range for appetite suppression. Some people report mild appetite reduction even at this dose, but in clinical trials, the measurable weight loss does not begin in earnest until patients reach 1.0 mg or higher. So staying at 0.25 mg longer is a trade-off: more comfort now, but a longer path to the dose that actually drives results.

On the flip side, you should not shorten the 0.25 mg phase. Even if you feel perfectly fine with no side effects at all, the four-week minimum allows semaglutide to approach steady-state blood levels at that dose.¹ Skipping ahead early, even by a week, means you are stacking a dose increase on top of blood levels that have not yet plateaued, which increases the odds of side effects at the next step.

Side Effects During the First Month

The 0.25 mg phase is generally the gentlest part of the Wegovy experience, but it is not symptom-free for everyone. The most commonly reported side effects are nausea, mild stomach pain, constipation, and diarrhea. These tend to be worst in the first few days after each injection and improve over the course of the week. Most people describe the nausea as a low-grade queasiness rather than the intense waves that can accompany higher doses.

A few practical tips make the first month easier. Eating smaller meals helps because semaglutide slows gastric emptying even at low doses, and a large meal sitting in a sluggish stomach is a recipe for discomfort. Fatty and greasy foods tend to worsen nausea more than lean proteins or simple carbohydrates. Staying well hydrated matters because both diarrhea and reduced food intake can leave you mildly dehydrated, which compounds the queasy feeling. And timing your injection so that the peak side-effect window falls on a less demanding day (many people inject on Friday evenings so the worst of any nausea lands on Saturday) is a common strategy.

Injection-site reactions are possible but uncommon and typically mild: a small red mark or slight tenderness that resolves within a day. Rotating between your abdomen, thigh, and upper arm helps minimize this.

What Changes When You Move to 0.5 mg

After four weeks (or longer, if your prescriber extends the ramp), you step up to 0.5 mg. This is still an escalation dose, not the maintenance target, but it is where many people first notice a real shift in appetite. The jump from 0.25 to 0.5 doubles the amount of drug you are injecting, though your circulating levels do not quite double because residual drug from the 0.25 mg phase is still present in your blood.

Side effects often flare modestly with each dose increase. The pattern most people describe is a few days of increased nausea after the first injection at the new dose, followed by gradual improvement over the next week or two. By the third or fourth injection at 0.5 mg, the side effects usually settle to a level similar to or milder than the initial days at 0.25 mg. This same pattern tends to repeat at 1.0 mg, 1.7 mg, and finally 2.4 mg, though the intensity varies from person to person.

Weight loss during the escalation phase is real but modest. Most of the dramatic results seen in clinical trials reflect the cumulative effect of spending months at the full 2.4 mg maintenance dose. Setting expectations early helps: the escalation is not where the magic happens. It is the runway.

Restarting After a Gap

Interruptions happen. Insurance issues, supply shortages, travel, or just forgetting a dose can create gaps in treatment. How you handle a restart depends on how long the gap lasted. If you missed a single weekly dose, the standard advice is to take your injection as soon as you remember and then return to your regular schedule. Semaglutide’s long half-life of roughly one week means that a single missed dose does not clear the drug from your system entirely.⁴

If the gap stretches beyond two weeks, things change. With a half-life of about seven days, after two weeks roughly 75% of the drug has been eliminated. After three to four weeks, you are essentially starting from scratch. In that scenario, most prescribers will restart the full escalation from 0.25 mg to avoid the GI shock of resuming at a dose your body is no longer adapted to. The gastroparesis case mentioned earlier is an extreme example of what can happen when a patient resumes at a high dose after a break without re-titrating.³

This is one of the more frustrating aspects of being on Wegovy. A month-long supply disruption does not just cost you a month of treatment. It effectively resets your escalation clock, adding another four months before you are back at the maintenance dose. The slow ramp is non-negotiable for safety, but it makes continuity of supply unusually important for this particular medication.

Kidney Disease and Other Special Populations

For most people, the standard four-week escalation through 0.25 mg applies regardless of other health conditions. Semaglutide does not appear to require dose adjustments for kidney impairment. A pharmacokinetic study comparing people with various degrees of kidney disease to those with normal kidney function found that drug exposure was broadly similar across groups. People with severe kidney impairment had roughly 22% higher semaglutide exposure on average, but after accounting for differences in age, sex, and body weight, the comparison fell within normal limits. Hemodialysis did not significantly alter how the drug behaved in the body.⁵

Similarly, liver impairment does not typically change the dose schedule. However, individual prescribers may choose to extend the time at lower doses for patients who are more medically complex or who are taking other medications that affect the GI tract. If you have a condition that already slows your digestion, like diabetes-related gastroparesis, the cautious approach is to spend extra time at each escalation step rather than rushing through.

Alternative Dosing Strategies Under Study

The fixed five-step schedule is the only FDA-approved approach for Wegovy, but researchers have begun modeling what might happen if dosing were adjusted differently. One pharmacokinetic modeling study looked at what would happen if patients took their maintenance dose less often rather than at a lower amount. The models predicted that taking 2.4 mg every two weeks instead of every week would retain about 72% of the weight loss achieved with weekly dosing, at half the drug cost. Similarly, switching from 1.7 mg weekly to 2.4 mg every two weeks was predicted to maintain about 82% of weight loss.⁶

These are modeling predictions, not results from clinical trials in real patients, and no regulatory body has approved an every-two-weeks schedule. But the research is driven by a real problem: Wegovy is expensive, supply has been inconsistent, and many people struggle to stay on the medication long-term. If extended-interval dosing could preserve most of the benefit at a fraction of the cost, it would change the economics of treatment dramatically. For now, though, the standard escalation starting at 0.25 mg weekly for four weeks remains the only evidence-based protocol.

Why Satisfaction Tends to Come Later

If you are in your first month on Wegovy and feeling underwhelmed, you are not alone. The 0.25 mg phase delivers side effects without much visible payoff, which can feel discouraging. Real-world survey data shows that user satisfaction with semaglutide is closely tied to the amount of weight lost, with satisfaction tipping into positive territory at an estimated weight reduction of about 12%.⁷ That level of loss takes months, well past the escalation phase and into sustained treatment at the maintenance dose.

The mismatch between expectation and early experience is one reason people abandon the medication prematurely. Understanding that the first month is purely a tolerability-building exercise, not a treatment phase, can help calibrate your expectations. The 0.25 mg dose is doing its job if you finish the four weeks able to tolerate the next step. Weight loss is not its job yet.